Osteoprotegerin and 25-hydroxy vitamin D levels in patients with diabetic foot

被引:15
作者
Caglar, Sever [1 ]
Caglar, Aysel [2 ]
Pilten, Saadet [3 ]
Albay, Cem [4 ]
Beytemur, Ozan [1 ]
Sari, Hakan [5 ]
机构
[1] Univ Hlth Sci, Bagcilar Training & Res Hosp, Dept Orthoped & Traumatol, TR-34100 Istanbul, Turkey
[2] Univ Hlth Sci, Bagcilar Training & Res Hosp, Dept Med Pathol, Istanbul, Turkey
[3] Univ Hlth Sci, Bagcilar Training & Res Hosp, Biochem Lab, Istanbul, Turkey
[4] Univ Hlth Sci, Baltalimani Training & Res Hosp, Dept Orthoped & Traumatol, Istanbul, Turkey
[5] Univ Hlth Sci, Bagcilar Training & Res Hosp, Dept Internal Med, Istanbul, Turkey
来源
EKLEM HASTALIKLARI VE CERRAHISI-JOINT DISEASES AND RELATED SURGERY | 2018年 / 29卷 / 03期
关键词
Diabetic foot; osteoprotegerin; vitamin D; 1,25-DIHYDROXYVITAMIN D-3; PLASMA-CONCENTRATIONS; SERUM-LEVELS; D DEFICIENCY; EXPRESSION; SEVERITY; ATHEROSCLEROSIS; RECEPTOR; MEN;
D O I
10.5606/ehc.2018.60797
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Objectives: This study aims to compare the levels of osteoprotegerin (OPG) and 25-hydroxy vitamin D (25(OH) D) in patients with diabetic foot and patients with newly diagnosed type 2 diabetes mellitus (DM) and to investigate the prevalence and severity of 25(OH) D insufficiency in patients with diabetic foot. Patients and methods: This prospective study was conducted on 105 patients including 58 patients with diabetic foot (42 males, 16 females; mean age 63.6 years; range, 31 to 90 years), who applied to our hospital between June 2014 and May 2015, and 47 newly diagnosed type 2 DM patients (27 males, 20 females; mean age 51.4 years; range, 29 to 85 years) (control group). 25(OH) D and osteoprotegerin serum levels in both groups were measured and compared. Results: Osteoprotegerin levels in diabetic foot group were significantly higher than the control group (p< 0.05). The 25(OH) D levels in diabetic foot group were significantly lower than the control group (p< 0.05). There were positive correlations between OPG levels and C-reactive protein (CRP) and creatinine levels in patients with diabetic foot. Conclusion: Elevated levels of OPG in patients with diabetic foot may display the severity of the clinical status due to its positive correlation with CRP and creatinine. We detected severe 25(OH) D deficiency in the majority of diabetic foot patients. Vitamin D supplementation may be required in diabetic foot patients to prevent unfavorable immunologic alterations.
引用
收藏
页码:170 / 175
页数:6
相关论文
共 27 条
[1]   Are all case reports worth publishing? [J].
Atik, O. Sahap .
EKLEM HASTALIKLARI VE CERRAHISI-JOINT DISEASES AND RELATED SURGERY, 2016, 27 (02) :61-61
[2]   Vitamin D3 and the immune system:: maintaining the balance in health and disease [J].
Baeke, Femke ;
Van Etten, Evelyne ;
Overbergh, Lut ;
Mathieu, Chantal .
NUTRITION RESEARCH REVIEWS, 2007, 20 (01) :106-118
[3]  
Cantorna MT, 2004, AM J CLIN NUTR, V80, p1717S, DOI 10.1093/ajcn/80.6.1717S
[4]  
Chiu KC, 2004, AM J CLIN NUTR, V79, P820
[5]   Activation of peroxisome proliferator-activated receptor γ inhibits osteoprotegerin gene expression in human aortic smooth muscle cefls [J].
Fu, MG ;
Zhang, JF ;
Lin, YM ;
Zhu, XJ ;
Willson, TM ;
Chen, YQE .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 294 (03) :597-601
[6]   Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease [J].
Jono, S ;
Ikari, Y ;
Shioi, A ;
Mori, K ;
Miki, T ;
Hara, K ;
Nishizawa, Y .
CIRCULATION, 2002, 106 (10) :1192-1194
[7]   Inhibitory effect of long term 1α-hydroxyvitamin D3 administration on Helicobacter pylori infection [J].
Kawaura, Akihiko ;
Takeda, Eiji ;
Tanida, Noritoshi ;
Nakagawa, Kimie ;
Yamamoto, Hironori ;
Sawada, Kenji ;
Okano, Toshio .
JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION, 2006, 38 (02) :103-106
[8]   Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure [J].
Kazama, JJ ;
Shigematsu, T ;
Yano, K ;
Tsuda, E ;
Miura, M ;
Iwasaki, Y ;
Kawaguchi, Y ;
Gejyo, F ;
Kurokawa, K ;
Fukagawa, M .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (03) :525-532
[9]   Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease [J].
Kiechl, S ;
Schett, G ;
Wenning, G ;
Redlich, K ;
Oberhollenzer, M ;
Mayr, A ;
Santer, P ;
Smolen, J ;
Poewe, W ;
Willeit, J .
CIRCULATION, 2004, 109 (18) :2175-2180
[10]   Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity [J].
Kim, SM ;
Lee, J ;
Ryu, OH ;
Lee, KW ;
Kim, HY ;
Seo, JA ;
Kim, SG ;
Kim, NH ;
Baik, SH ;
Choi, DS ;
Choi, KM .
CLINICAL ENDOCRINOLOGY, 2005, 63 (05) :594-598